Expression of midkine and its clinical significance in esophageal squamous cell carcinoma

World Journal of Gastroenterology

Volumn 12, Issue 13, 2006, Pages 2006-2010

  Ren, Ying Jia ^a   Zhang, Qing Yun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Esophageal squamous cell carcinoma; Expression; Midkine

Indexed keywords

MESSENGER RNA; MIDKINE; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOPLASM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION;

EID: 33646465741     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i13.2006     Document Type: Article

References (29)

1. Tomomura M, Kadomatsu K, Nakamoto M, Muramatsu H, Kondoh H, Imagawa K, Muramatsu T. A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commun 1990; 171: 603-609
2. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in midgestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151:1312-1318
3. Miyauchi M, Shimada H, Kadomatsu K, Muramatsu T, Matsubara S, Ikematsu S, Takenaga K, Asano T, Ochiai T, Sakiyama S, Tagawa M. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 1999; 90: 469-475
4. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, Muramatsu T. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655-661
5. Aridome K, Takao S, Kaname T, Kadomatsu K, Natsugoe S, Kijima F, Aikou T, Muramatsu T. Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas. Br J Cancer 1998; 78: 472-477
6. Ye C, Qi M, Fan QW, Ito K, Akiyama S, Kasai Y, Matsuyama M, Muramatsu T, Kadomatsu K. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 1999; 79: 179-184
7. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med 2000; 124: 848-852
8. Kato M, Shinozawa T, Kato S, Endo K, Terada T. Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. Liver 2000; 20: 216-221
9. Sakitani H, Tsutsumi M, Kadomatsu K, Ikematsu S, Takahama M, Iki K, Tsujiuchi T, Muramatsu T, Sakuma S, Sakaki T, Konishi Y. Overexpression of midkine in lung tumors induced by N-nitrosobis(2-hydroxypropyl) amine in rats and its increase with progression. Carcinogenesis 1999; 20: 465-469
10. Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol 2000; 13:1060-1065
11. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladdercancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996; 56: 2515-2518
12. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao Y, Muramatsu T, Kadomatsu K. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999; 57: 253-257
13. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995; 55: 1792-1797
14. Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, Muramatsu. T, Kirino T. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997; 233: 29-32
15. Kato S, Ishihara K, Shinozawa T, Yamaguchi H, Asano Y, Saito M, Kato M, Terada T, Awaya A, Hirano A, Dickson DW, Yen SH, Ohama E. Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. J Neuropathol Exp Neurol 1999; 58: 430-441
16. Zhang QY, Yang M, Wang YM, Xu JJ. Expression of midkine fusion protein and preparation and application of its monoclonal antibodies. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2005; 21: 605-608
17. Aaronson SA. Growth factors and cancer. Science 1991; 254: 1146-1153
18. Kadomatsu K, Huang RP, Suganuma T, Murata F, Muramatsu T. A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 1990; 110: 607-616
19. Muramaki M, Miyake H, Hara I, Kamidono S. Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. Clin Cancer Res 2003; 9: 5152-5160
20. Kojima S, Muramatsu H, Amanuma H, Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995; 270: 9590-9596
21. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001; 61:8486-8491
22. Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer 2005; 114: 490-497
23. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K. Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by Midkine. J Biochem (Tokyo) 2000; 127: 269-277
24. Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, Muramatsu T. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 2001; 167: 3463-3469
25. Beecken WD, Kramer W, Jonas D. New molecular mediators in tumor angiogenesis. J Cell Mol Med 2000; 4: 262-269
26. Wu X, Yao, J, Li Q, Zheng H, Xin Y. Expression of midkine in benign, premalignant and malignant vulvar tumors. Chin Med Sci J 2002; 17: 148-152
27. Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, Okamoto K, Oda M, Sakuma S, Aikou T, Muramatsu H, Kadomatsu K, Muramatsu T. Serum midkine levels are increased in patients with various types of carcinomas. Br Cancer 2000; 83: 701-706
28. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003; 94: 628-632
29. Ikematsu S, Okamoto K, Yoshida Y, Oda M, Sugano-Nagano H, Ashida K, Kumai H, Kadomatsu K, Muramatsu H, Takashi Muramatsu, Sakuma S. High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun 2003; 306: 329-332